Get the latest tech news
Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
There's growing evidence that GLP-1 drugs, which include Ozempic and Wegovy, may benefit the brain.
Novo Nordisk, which makes Ozempic and Wegovy, is running two phase 3 clinical trials comparing semaglutide to a placebo in more than 3,000 patients with mild cognitive impairment or early-stage Alzheimer’s disease. If those trial results are positive, semaglutide “would be a game changer, adding a whole new treatment option that we didn’t previously have in our tool kit,” said Dr. Stephen Salloway, a professor of neurology at Warren Alpert Medical School of Brown University in Rhode Island. The Food and Drug Administration has approved two treatments — Biogen’s Leqembi and Lilly’s Kisunla — that marginally slow the progression of the illness by targeting the disease’s hallmark amyloid plaques in the brain.
Or read this on Hacker News
